PBS updates

Imbruvica (Ibrutinib)

ibrutinib 280 mg tablet, 30 · ORAL · PBS code 14580J

AUTHORITY_REQUIRED

What it costs

AU$5194.37 PBS-determined price per 30 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2024-10-01.
  • • Repeats: 2.
  • • PBS program: GE.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)


Initial treatment in first-line therapy (treatment cycles 1 to 3 inclusive)


The condition must be untreated with drug treatment at the time of the first dose of this drug; or

Patient must have developed an intolerance of a severity necessitating permanent treatment withdrawal following use of another drug PBS indicated as first-line drug treatment of CLL/SLL; AND

The treatment must only be prescribed for a patient with active disease in accordance with the International Workshop on CLL (iwCLL) guidance (latest version) in relation to when to prescribe drug treatment for this condition; AND

The treatment must be in combination with venetoclax (refer to Product Information for timing of ibrutinib and venetoclax doses).

There are more ibrutinib capsules (or tablets) in a pack than is required for the completion of a treatment cycle. The patient must not discard any remaining capsules (or tablets) after the completion of any treatment cycle as these capsules (or tablets) will be required for the doses in the final treatment cycle (i.e. treatment cycle 15).

Sponsor: Janssen-Cilag Pty Ltd ABN 47 000 129 975

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.